View Post

Straight to the lungs: Inhaled chemo lessens collateral damage

In Clinical Trials by Barbara Jacoby

By: Katrina Burton From: mdanderson.org MD Anderson researchers are examining the use of inhaled chemotherapy to treat cancer that has spread to the lungs from other sites in the body. They hope to find that the inhaler delivers the chemotherapy drug directly to the lungs where it treats lung tumors while sparing healthy organs. A new way of treating cancer …

View Post

IACS and other platforms develop new cancer treatments for clinical trials

In Clinical Trials by Barbara Jacoby

By: Clayton R. Boldt, Ph.D. From: mdanderson.org Therapeutics Discovery scientists bring clinical cancer research to the lab and use unique model for drug development to benefit cancer patients. “From the bench to the bedside” is a phrase often used to describe a drug discovery’s journey from the laboratory to the clinic, where patients benefit. MD Anderson’s Therapeutics Discovery division, however, …

View Post

Immunotherapy for lung cancer: Researchers working to broaden its reach

In Clinical Trials by Barbara Jacoby

By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …

View Post

Study of tagraxofusp reports 90% response rate for deadly blood cancer with no prior available therapies

In Clinical Trials by Barbara Jacoby

Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone …

View Post

Cutting-edge MRI-guided radiation therapy provides real-time view of tumors

In In The News by Barbara Jacoby

By: Ronda Wendler From: mdanderson.org An innovative new technology is now providing radiation oncologists at MD Anderson Cancer Center a real-time view of tumors while they use cancer-killing radiation beams. These live images help keep the radiation beam directly on target throughout every treatment, allowing for a degree of precision and monitoring capabilities that were not previously possible. Marriage of …

View Post

Research to remove exclusions on immunotherapy

In Clinical Trials by Barbara Jacoby

By: Michael Hardy From: mdanderson.org People used to ask Patrick Hwu, M.D., why he decided to devote his career to melanoma, a skin cancer with high mortality rates and limited treatment options. “They would come up to me and say, ‘How can you treat advanced melanoma? Isn’t that depressing?’ And actually, it was — my clinic of advanced melanoma patients …

View Post

9 things to know about CAR T-cell therapy

In Clinical Trials by Barbara Jacoby

By: Cynthia DeMarco From: mdanderson.org CAR T-cell therapy is a new type of cancer treatment offered at MD Anderson through clinical trials and FDA-approved standard of care cell therapy products. But what exactly is CAR T-cell therapy? And who should consider it? We spoke with Sattva Neelapu, M.D., to learn more. Here’s what he had to say. Let’s start with the …

First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain

In Clinical Trials by Barbara Jacoby

Small molecule lead drug candidate blocks a critical target for tumors and crosses the blood brain barrier; begins first brain cancer patient dosing in clinical trial at MD Anderson Cancer In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized to the brain, the pharmaceutical company Moleculin Biotech, Inc., (Nasdaq: MBRX) has initiated …

View Post

Researchers compose guidelines for handling CAR T cell side effects

In In The News by Barbara Jacoby

From: mdanderson.org Detailed procedures are designed to protect patients from promising treatment’s toxicities Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for systematically dealing with …

Social isolation may worsen breast cancer prospects

In In The News by Barbara Jacoby

By: Liz Szabo, Kaiser Health News Patients with early breast cancer who are socially isolated have a higher risk of dying from their disease, a new study suggests. Women with fewer social ties — to friends, family, community and religious groups, as well as spouses or romantic partners — were 43 percent more likely to see their breast cancer return, …